pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

638 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1888Endpoints1464Fierce Biotech779BioSpace767BioPharma Dive554raps254onclive165fda recalls
therapy area
allOncology13092Rare Disease3386Immunology3069Cardiology2865Hematology2334Pulmonology2297Vaccines
  • FDA delays decision on Belite Bio's Stargardt disease drug to May 12
    The FDA announced it will extend its review of Belite Bio's new drug application for tinlarebant, an oral small-molecule intended to treat Stargardt disease type 1, moving the PDUFA action date fro…
    Fierce Biotech · 9h agoRegulatoryNeutral↗ source
  • Scientists study blood markers for chronic traumatic encephalopathy using samples from 21 football players
    Researchers collected blood from 21 current football players and arranged for their brains to be donated after death to support chronic traumatic encephalopathy (CTE) research. The team is analyzi…
    STAT · 4h agoNeutral↗ source
← prev
page 1 of 26
next →
122
fda medwatch117
globenewswire health73
fda press62
1882
Psychiatry & CNS1247
Ophthalmology1150
Endocrinology & Metabolism809
Pain801
Nephrology789
  • FDA approves treatments for four rare diseases; Pfizer inks $2.6 billion China licensing deal for CAR‑T therapy
    The U.S. Food and Drug Administration has granted approval for drugs targeting four distinct rare diseases, expanding therapeutic options for patients with limited treatment choices. In a separate…
    raps · 1d agoApprovalPositive↗ source
  • Merck partners with Isomorphic Labs to use AI for discovering oncology drug candidates
    Merck announced a research collaboration with Isomorphic Labs, an artificial‑intelligence drug design firm, to explore small‑molecule candidates aimed at an undisclosed oncology target. Isomorphic…
    STAT · 1d agoDealPositive↗ source
  • Novartis CEO says shareholders remain supportive despite recent trial setbacks
    Novartis chief executive Vas Narasimhan told Fierce that, despite a series of recent clinical setbacks, most shareholders continue to back the company’s long-term strategy. The setbacks include th…
    Fierce Biotech · 1d agoPositive↗ source
  • National Academies urges faster retractions and corrections to protect scientific record
    The National Academies of Sciences, Engineering, and Medicine released a report urging the scientific community to act more quickly when errors or data manipulation are identified in published rese…
    STAT · 1d agoPositive↗ source
  • Early Alert: B. Braun Medical Inc. Updates Use Instructions for Caresite Micro Luer Access Device
    BBMI corrects Caresite devices due to issue with internal piston remaining depressed following disconnection, preventing the valve from fully closing.
    fda medwatch · 1d agoRegulatoryNeutral↗ source
  • FDA approves Infilbray, first therapy for neurological symptoms of Type 3 Gaucher disease
    The U.S. Food and Drug Administration has approved Infilbray (venglustat) tablets for treating the neurological manifestations of Type 3 Gaucher disease in adults and children weighing at least 15…
    fda press · 1d agoApprovalPositive↗ source
  • FDA Approves First Drug Shown to Help Patients with Infantile-Onset Niemann-Pick Disease Type C Live Longer
    FDA approved Lembaz (adrabetadex) injection, the first treatment shown to help people with a severe form of Niemann-Pick disease type C (NPC) live longer.
    fda press · 2d agoApprovalPositive↗ source
  • Capsida proposes new monkey testing framework after fatal gene therapy trial for brain disease
    Researchers presented investigations into a patient death that occurred in a gene therapy trial for a brain disease, which had raised concerns in the field. While the exact cause of death was not…
    STAT · 3d agoNegative readoutNegative↗ source
  • Mount Sinai researchers map enzyme structure linked to rare metabolic disorder GA1
    Researchers at Icahn School of Medicine at Mount Sinai have determined the crystal structure of an upstream enzyme involved in glutaric aciduria type 1 (GA1), a rare neuro‑metabolic disease. GA1 r…
    Fierce Biotech · 3d agoPositive readoutPositive↗ source
  • Marrow Therapeutics raises $173 million to develop infusion therapy for sickle cell disease
    Marrow Therapeutics was announced on Tuesday by biotech entrepreneur Romesh Subramanian. The new company aims to create an infusion therapy for sickle cell disease that matches the efficacy of gene…
    STAT · 3d agoDealPositive↗ source
  • John Powers III named permanent director of NIH's National Institute of Allergy and Infectious Diseases
    NIH's National Institute of Allergy and Infectious Diseases (NIAID) has finally filled its top leadership vacancy that has persisted since 2025. The institute had been led in an acting capacity by…
    STAT · 3d agoNeutral↗ source
  • Eli Lilly acquires Calytrix Bio in $1.5 billion deal to add myelofibrosis antibody to its pipeline
    Eli Lilly announced a $1.5 billion acquisition of Massachusetts‑based Calytrix Bio, gaining access to the company’s biparatopic antibody aimed at mutant calreticulin‑driven essential thrombocythemi…
    Fierce Biotech · 4d agoDealPositive↗ source
  • Sellas vaccine shows 9-month overall survival gain in phase 3 AML trial
    Sellas Life Sciences reported results of a phase 3 trial of its peptide vaccine galinpepimut-S (GPS) in patients with acute myeloid leukemia (AML). The study met its primary endpoint, showing a me…
    Fierce Biotech · 3d agoPositive readoutPositive↗ source
  • FDA rejects ivonescimab for lung cancer; J&J to acquire Ollin Biosciences for up to $3.3B, Senate votes on FDA commissioner
    The FDA has denied the application for ivonescimab as a treatment for lung cancer, halting its development for that indication. Johnson & Johnson announced a deal to purchase Ollin Biosciences, a…
    raps · 4d agoRegulatoryNeutral↗ source
  • Versant and Eli Lilly commit $100 million to launch Seawolf Therapeutics, a non-viral gene-therapy startup
    Versant Ventures, Eli Lilly and other investors announced a $100 million financing round to create Seawolf Therapeutics, a new company focused on non-viral gene delivery. The startup aims to overc…
    STAT · 4d agoDealPositive↗ source
  • Takeda narcolepsy pill receives DEA clearance as Oura-Lilly deal raises conflict concerns and Pfizer exits Canadian Premarin market
    Takeda announced that its experimental narcolepsy medication has been cleared by the U.S. Drug Enforcement Administration, marking the first regulatory nod for a therapy aimed at treating excessive…
    STAT · 7d agoRegulatoryPositive↗ source
  • Oura to acquire telehealth firm Counsel Health, raising conflict-of-interest concerns for Eli Lilly
    Oura, known for its smart rings, announced it will purchase Counsel Health, a telehealth startup that connects patients with clinicians for GLP-1 prescriptions. The acquisition will give Counsel c…
    STAT · 7d agoDealNeutral↗ source
  • FDA issues warning letters to three Chinese API makers over record refusals and quality oversight lapses
    The U.S. Food and Drug Administration sent warning letters to three manufacturers of active pharmaceutical ingredients (APIs) based in China. Two of the companies were cited for refusing to provid…
    raps · 7d agoRegulatoryNegative↗ source
  • FDA issues warning letters to three Chinese API makers over record refusals and quality oversight lapses
    The FDA sent warning letters to three active pharmaceutical ingredient manufacturers based in China. Two firms were cited for refusing the agency's requests for records, while the third was found…
    raps · 7d agoRegulatoryNeutral↗ source
  • Senator-elect Abdul El-Sayed vows to rebuild trust in science amid rising measles and other health threats
    Senator-elect Abdul El‑Sayed is set to become the first epidemiologist to serve in the U.S. Senate, a timing that coincides with a series of public‑health challenges across the country. More than…
    STAT · 7d agoNeutral↗ source
  • Sofinnova Partners closes €725 million (≈$815 million) Crossover II fund to back ~15 European clinical-stage biotech firms
    Sofinnova Partners announced the closing of its largest fund to date, Crossover II, with €725 million (about $815 million) in capital. The fund plans to invest in roughly 15 clinical‑stage compani…
    Fierce Biotech · 7d agoDealPositive↗ source
  • STAT+: Blackstone backs Pfizer’s bet on monthly obesity treatment
    Pfizer spent up to $10 billion to buy Metsera last year. Now, it’s bringing in private equity behemoth Blackstone to help pay for the deal.
    STAT · 8d agoRegulatoryNeutral↗ source
  • U.S. 'most-favored nations' policy prompts drugmakers to reconsider overseas launches
    The White House's "most-favored nations" rule, which would tie foreign drug prices to U.S. prices, is causing U.S. pharma firms to rethink launching products abroad. Companies are exploring strate…
    STAT · 8d agoRegulatoryNeutral↗ source